Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoCol
2024-514294-22-01Phase 3Authorised
- Sponsor
- Sygehus Lillebælt
- Start
- Sep 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised trial of capecitabine and oxaliplatin in colon cancer (2 arms), sponsored by Sygehus Lillebælt. Primary endpoint: Two-year disease-free survival. Planned start Sep 2024; status: authorised.
02
Drugs
capecitabineoxaliplatin
03
Conditions
colon cancer
Beyond the preview
Go deeper on 2024-514294-22-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514294-22-01.